subject: Top 5 Generic Drug Manufacturers [print this page] Top 5 Generic Drug Manufacturers Top 5 Generic Drug Manufacturers
Hello dear readers!
In my last post i wrote about "Choosing an online pharmacy".Now,the one thing forgot to add to that post is Generic Drug Manufactures!As it is really important where does the online pharmacy gets their drugs.So in this post i'm going to tell you about the best 5 Generic Drug Manufacturers in the world.That way you can figure out quality of generic drugs that are avalible in online pharmacy.
Most of Generic Drugs Manufacturers are located in India and Canada, because of their countries health politics.They are manufacturing most of the generics.Other manufacturers are located in Europe(the biggest one is in Germany) and USA.
Here is a quick review of each of the 5 companies:
1)Teva Pharmaceuticals
Israel-based Teva Pharmaceuticals is one of the largest generic drug maker in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Almost 90 percent of the company's sales are in North America and Europe.
In January, Teva acquired Sicor, a multinational pharmaceutical company that focuses on generic finished-dosage injectables, active pharmaceutical ingredients and generic biopharmaceuticals.
The generic drug maker also entered a strategic collaboration with Andrx Corp. to develop and market oral contraceptives. The alliance gives Teva exclusive marketing rights to Previfem (norgestimate and ethinyl estradiol), the newly approved abbreviated new drug application and bioequivalent of Ortho Cyclen-28, an Ortho McNeil Pharmaceutical oral contraceptive product. Teva also has marketing rights to Andrx's entire line of generic oral contraceptives currently awaiting Food and Drug Administration approval.
In December, Teva received tentative FDA approval for terbinafine hydrochloride tablets, the generic equivalent to Novartis' antifungal agent Lamisil, with annual sales of about $541 million.
Total Sales: $1,272.6
Total market share:11.3%
2)Mylan Pharmaceuticals
Mylan Laboratories develops, manufactures and markets an extensive line of generic and proprietary prescription drugs. The generic segment consists of two principal business units, Mylan Pharmaceuticals and UDL Laboratories, both wholly owned subsidiaries. Mylan's generic product portfolio includes immediate- and extended-release oral tablets, capsules and transdermal patches.
In the last half of 2003, Mylan received FDA approval for its fentanyl transdermal system, the generic version of Alza Corp.'s pain patch, Duragesic, with sales in excess of $1 billion for the 12 months ended in June. Mylan also received ANDA approvals for nefazodone hydrochloride tablets, the generic version of Bristol-Myers Squibb's depression drug, Serzone, and for 10 mg and 20 mg omeprazole delayed-release capsules, the generic version of AstraZeneca LP's heartburn medication, Prilosec.
Total Sales: $1,008.7
Total market share:9.0%
3)Watson Pharma
Watson is the fifth-largest U.S. pharmaceutical company in terms of prescriptions dispensed, numbering 173 million in 2003. In 2002, its revenue mix was 45 percent generic and 55 percent branded. The company launched 16 generic drugs on the market in 2003.
In 2003, Watson announced that it would expand its generic product development by forming an alliance with Cipla Ltd., the second-largest pharmaceutical company in India. Under the agreement, Cipla will manufacture generic drugs, and Watson will have exclusive U.S. marketing rights.
Watson's notable genetic approvals in 2003 include glipizide extended-release tablets, the generic equivalent of Pfizer's Glucotrol XL for treating type 2 diabetes. For the 12 months ended in September, Glucotrol XL had sales of about $345 million. Watson also launched oxycodone/APAP, the generic equivalent to Endo Pharmaceuticals' Percocet tablets for moderate to moderately severe pain. For the 12 months ended in August, Percocet had sales of about $157 million.
Total Sales: $ 865.1
Total market share:7.7 %
4)Sandoz
Geneva Pharmaceuticals, a Novartis-owned company, announced it would conduct all business operations under the name Sandoz. The move united 14 different generic drug units under one common name. Today, Sandoz manufactures more than 200 generic pharmaceutical products in more than 500 package sizes.
Sandoz's U.S. retail pharmaceuticals business and the integration of Slovenian pharmaceutical company Lek drove its full-year sales. The company posted strong sales growth in fourth quarter 2003, despite intense competition for AmoxC, the company's generic version of GlaxoSmithKline's antibiotic, Augmentin. In 2003, Sandoz also acquired Amifarma in Spain, strengthening its antibiotics production capacity and technology.
Sandoz files about 800 submissions annually for new products in close to 100 countries worldwide. The generic drug maker focuses primarily on product groups that include anti-infectives, anti-arthritics, cardiovascular drugs, gastrointestinal agents and psychotherapeutics.
Total Sales: $ 734.7
Total market share:6.5 %
5)Ivax
Ivax is a multinational pharmaceutical corporation dedicated to the research, development, manufacturing, marketing and distribution of branded and generic drugs.
In December, the company entered an agreement with Hungary-based Gedeon Richter Ltd., under which a number of genetic drugs will be developed for the U.S. market and distributed by Ivax.
Also in December, the company began distributing its oral antibacterial combination amoxicillin with clavulanate potassium. The drug is the generic equivalent of Augmentin, marketed by GlaxoSmithKline, with U.S. sales of $1.4 billion for the 12 months ended Sept. 30.
In late 2003, Ivax received tentative FDA approval for its ANDA for gabapentin capsules, the generic equivalent of Pfizer's anti-epileptic drug, Neurontin.
